Krafft W, Behling H, Schirmer A, Brückmann D, Preibsch W, Kademann J, Marzotko F, Schmeisser G
Zentralbl Gynakol. 1979;101(7):468-72.
A report is given about the efficiency of the so called adjuvant chemotherapy in 26 cases (26 patients suffering from ovarian cancer in the stage T1M0N0) in a time of 10 years (1968-1977).--After the primary operation-therapy, a part of the patients (9) got the cytostatic drugs Trenimon or Cyclophosphamid. The patients of the control group got nothing. The survival times of both groups showed no significant distinctions. -- The results show that the adjuvant chemotherapy in cases of ovarian cancers in stage T1M0N0 can not be recommended because there are too many side effects of the these cytostatic drugs.
本文报告了在10年期间（1968 - 1977年），对26例（26名处于T1M0N0期的卵巢癌患者）使用所谓辅助化疗的疗效。——在进行初次手术治疗后，部分患者（9例）接受了细胞毒性药物三嗪咪唑胺或环磷酰胺治疗。对照组患者未接受任何治疗。两组患者的生存时间没有显著差异。——结果表明，对于T1M0N0期卵巢癌患者，不建议使用辅助化疗，因为这些细胞毒性药物的副作用太多。
